Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric cancer.

Mitsuro KandaNao TakanoHiroshi MiyauchiKohei UedaMasaaki MizunoYuuya KasaharaYasuhiro KoderaSatoshi Obika

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)

The preclinical profile of intra-abdominal administration of ASO-4733 demonstrated its suitability for entry into clinical trials of patients with peritoneal metastasis of gastric cancer.

Keyphrases

nucleic acid
clinical trial
cell therapy
cancer therapy
randomized controlled trial
stem cells
open label
replacement therapy
phase iii